188 related articles for article (PubMed ID: 31217744)
1. Inhibition of N822K T>A mutation-induced constitutive c-KIT activation in AML cells triggers apoptotic and autophagic pathways leading to death.
Xu J; Zheng J; Fu X; Wu W; Tao L; Li D; Lin D
Int J Med Sci; 2019; 16(5):757-765. PubMed ID: 31217744
[No Abstract] [Full Text] [Related]
2. BPR1J373, an Oral Multiple Tyrosine Kinase Inhibitor, Targets c-KIT for the Treatment of c-KIT-Driven Myeloid Leukemia.
Chen LT; Chen CT; Jiaang WT; Chen TY; Butterfield JH; Shih NY; Hsu JT; Lin HY; Lin SF; Tsai HJ
Mol Cancer Ther; 2016 Oct; 15(10):2323-2333. PubMed ID: 27512117
[TBL] [Abstract][Full Text] [Related]
3. D816V mutation in the KIT gene activation loop has greater cell-proliferative and anti-apoptotic ability than N822K mutation in core-binding factor acute myeloid leukemia.
Omori I; Yamaguchi H; Miyake K; Miyake N; Kitano T; Inokuchi K
Exp Hematol; 2017 Aug; 52():56-64.e4. PubMed ID: 28506695
[TBL] [Abstract][Full Text] [Related]
4. N822K- or V560G-mutated KIT activation preferentially occurs in lipid rafts of the Golgi apparatus in leukemia cells.
Obata Y; Hara Y; Shiina I; Murata T; Tasaki Y; Suzuki K; Ito K; Tsugawa S; Yamawaki K; Takahashi T; Okamoto K; Nishida T; Abe R
Cell Commun Signal; 2019 Sep; 17(1):114. PubMed ID: 31484543
[TBL] [Abstract][Full Text] [Related]
5. Dasatinib inhibits proliferation and induces apoptosis in the KASUMI-1 cell line bearing the t(8;21)(q22;q22) and the N822K c-kit mutation.
Mpakou VE; Kontsioti F; Papageorgiou S; Spathis A; Kottaridi C; Girkas K; Karakitsos P; Dimitriadis G; Dervenoulas I; Pappa V
Leuk Res; 2013 Feb; 37(2):175-82. PubMed ID: 23149070
[TBL] [Abstract][Full Text] [Related]
6. The Hsp90 inhibitor 17-allylamide-17-demethoxygeldanamycin induces apoptosis and differentiation of Kasumi-1 harboring the Asn822Lys KIT mutation and down-regulates KIT protein level.
Yu W; Rao Q; Wang M; Tian Z; Lin D; Liu X; Wang J
Leuk Res; 2006 May; 30(5):575-82. PubMed ID: 16213582
[TBL] [Abstract][Full Text] [Related]
7. Cytological and spectroscopic characteristics of c-KIT N822K mutation in core binding factor acute myeloid leukemia cells.
Chen Y; Wang L; Lin X; Zhang Q; Xu Y; Lin D; Xu J; Feng S; Hu J
J Biophotonics; 2020 Aug; 13(8):e202000103. PubMed ID: 32390317
[TBL] [Abstract][Full Text] [Related]
8. Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia.
Hu S; Niu H; Minkin P; Orwick S; Shimada A; Inaba H; Dahl GV; Rubnitz J; Baker SD
Mol Cancer Ther; 2008 May; 7(5):1110-20. PubMed ID: 18483300
[TBL] [Abstract][Full Text] [Related]
9. Reactivating PP2A by FTY720 as a novel therapy for AML with C-KIT tyrosine kinase domain mutation.
Yang Y; Huang Q; Lu Y; Li X; Huang S
J Cell Biochem; 2012 Apr; 113(4):1314-22. PubMed ID: 22109829
[TBL] [Abstract][Full Text] [Related]
10. Polyphyllin I Inhibits Proliferation and Induces Apoptosis by Downregulating AML1-ETO and Suppressing C-KIT/Akt Signaling in t(8;21) Acute Myeloid Leukemia.
Chai Y; Si Y; Xu J; Xiang Y; Zhao H; Si Y; Zhang T; Liu Y
Chem Biodivers; 2018 Nov; 15(11):e1800314. PubMed ID: 30194712
[TBL] [Abstract][Full Text] [Related]
11. Functional Properties of
Tarlock K; Alonzo TA; Wang YC; Gerbing RB; Ries R; Loken MR; Pardo L; Hylkema T; Joaquin J; Sarukkai L; Raimondi SC; Hirsch B; Sung L; Aplenc R; Bernstein I; Gamis AS; Meshinchi S; Pollard JA
Clin Cancer Res; 2019 Aug; 25(16):5038-5048. PubMed ID: 31182436
[TBL] [Abstract][Full Text] [Related]
12. The Kasumi-1 cell line: a t(8;21)-kit mutant model for acute myeloid leukemia.
Larizza L; Magnani I; Beghini A
Leuk Lymphoma; 2005 Feb; 46(2):247-55. PubMed ID: 15621809
[TBL] [Abstract][Full Text] [Related]
13. Transitory dasatinib-resistant states in KIT(mut) t(8;21) acute myeloid leukemia cells correlate with altered KIT expression.
Herrmann MD; Lennerz JK; Bullinger L; Bartholomae S; Holzmann K; Westhoff MA; Corbacioglu S; Debatin KM
Exp Hematol; 2014 Feb; 42(2):90-100. PubMed ID: 24211243
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of CDK4/6 and autophagy synergistically induces apoptosis in t(8;21) acute myeloid leukemia cells.
Nakatani K; Matsuo H; Harata Y; Higashitani M; Koyama A; Noura M; Nishinaka-Arai Y; Kamikubo Y; Adachi S
Int J Hematol; 2021 Feb; 113(2):243-253. PubMed ID: 33068248
[TBL] [Abstract][Full Text] [Related]
15. [Effect of tyrosine kinase inhibitor Imatinib mesylate on proliferation, differentiation and apoptosis of Kasumi-1 leukemia cell line].
Wang LH; Rao Q; Wang M; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2005 Aug; 26(8):449-52. PubMed ID: 16383232
[TBL] [Abstract][Full Text] [Related]
16. Core binding factor acute myeloid leukaemia and c-KIT mutations.
Riera L; Marmont F; Toppino D; Frairia C; Sismondi F; Audisio E; Di Bello C; D'Ardia S; Di Celle PF; Messa E; Inghirami G; Vitolo U; Pich A
Oncol Rep; 2013 May; 29(5):1867-72. PubMed ID: 23467883
[TBL] [Abstract][Full Text] [Related]
17. Sensitivity of acute myeloid leukemia Kasumi-1 cells to binase toxic action depends on the expression of KIT and АML1-ETO oncogenes.
Mitkevich VA; Petrushanko IY; Spirin PV; Fedorova TV; Kretova OV; Tchurikov NA; Prassolov VS; Ilinskaya ON; Makarov AA
Cell Cycle; 2011 Dec; 10(23):4090-7. PubMed ID: 22101339
[TBL] [Abstract][Full Text] [Related]
18. D816 mutation of the KIT gene in core binding factor acute myeloid leukemia is associated with poorer prognosis than other KIT gene mutations.
Yui S; Kurosawa S; Yamaguchi H; Kanamori H; Ueki T; Uoshima N; Mizuno I; Shono K; Usuki K; Chiba S; Nakamura Y; Yanada M; Kanda J; Tajika K; Gomi S; Fukunaga K; Wakita S; Ryotokuji T; Fukuda T; Inokuchi K
Ann Hematol; 2017 Oct; 96(10):1641-1652. PubMed ID: 28762080
[TBL] [Abstract][Full Text] [Related]
19. [Scanning of c-kit gene mutations in acute myeloid leukemias using high-resolution melting analysis].
Yao DM; Qian J; Lin J; Chen Q; Xiao GF; Wang YL; Qian Z; Ji RB; Li Y; Yang J
Zhonghua Xue Ye Xue Za Zhi; 2011 Jan; 32(1):21-4. PubMed ID: 21429396
[TBL] [Abstract][Full Text] [Related]
20. Cooperating mutations of receptor tyrosine kinases and Ras genes in childhood core-binding factor acute myeloid leukemia and a comparative analysis on paired diagnosis and relapse samples.
Shih LY; Liang DC; Huang CF; Chang YT; Lai CL; Lin TH; Yang CP; Hung IJ; Liu HC; Jaing TH; Wang LY; Yeh TC
Leukemia; 2008 Feb; 22(2):303-7. PubMed ID: 17960171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
